FDA Peptide Meeting July 2026: What PCAC Recommended for All Seven Peptides

FDA Peptide Meeting July 2026: What PCAC Recommended for All Seven Peptides

By the Generic Peptides Team

Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal advice. None of the seven peptides discussed below became an FDA-approved drug as a result of the meeting.

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) completed a two-day review of seven widely discussed peptides: BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Epitalon, and Semax.

The headline result was straightforward: PCAC supported six of the seven peptide groups for possible inclusion on the Section 503A Bulks List. Emideltide, commonly called DSIP, was the only one that did not receive a positive recommendation.

But PCAC is an advisory committee. Its votes did not approve six drugs, establish safety or effectiveness, or automatically add the substances to the 503A Bulks List. Final regulatory action remains with FDA.

July 2026 PCAC Results at a Glance

FDA's formal questions treated the free-base and acetate forms as distinct bulk drug substances. The table summarizes the committee outcome for each peptide group; it should not be read as a finding that every material marketed under the same common name is chemically equivalent.

What Changed—and What Did Not

Six peptide groups now have a favorable PCAC recommendation that FDA can consider. The votes did not:

• make any of the peptides FDA-approved drugs;
• prove safety or effectiveness for the evaluated uses;
• automatically place any substance on the 503A Bulks List;
• authorize compounding solely because of the committee vote;
• create an approved indication, dose, route, formulation, or treatment protocol; or
• change the research-only status of laboratory products.

When a bulk substance lacks an applicable USP or National Formulary monograph and is not a component of an FDA-approved drug, appearance on the 503A Bulks List can be one condition for qualifying patient-specific compounding. Other federal and state requirements still apply. "PCAC recommended inclusion" and "FDA approved the peptide" are therefore not interchangeable statements.

Why the Votes Were Controversial

FDA staff's scientific reviews generally argued against including the seven peptide groups. Recurring concerns included incomplete chemical characterization, peptide-related impurities and aggregation, limited route-specific safety information, weak or absent human evidence, and insufficient proof of effectiveness. PCAC nevertheless reached favorable recommendations for six groups, weighing the statutory criteria and compounding context differently from FDA staff.

Several votes were narrow. BPC-157, KPV, and TB-500 were each reported as receiving eight votes in favor, six against, and one abstention. MOTS-c also passed by a divided vote. Emideltide failed by a narrow margin. The results therefore should not be described as a broad scientific consensus that the evidence gaps have been resolved.

What PCAC Recommended for Each Peptide

BPC-157: Favorable Recommendation for the Ulcerative-Colitis Nomination

BPC-157's July review focused on ulcerative colitis—not the tendon, muscle, joint, or general recovery claims that dominate online discussion.

FDA identified limited human information, including an exploratory ulcerative-colitis study, but considered the record insufficient to establish effectiveness or adequately characterize safety. Staff also raised questions about impurities, aggregates, naming, and the differences between the free-base and acetate forms. PCAC recommended inclusion despite that assessment. Researchers can review the stated identity and batch documentation on the BPC-157 research peptide page.

KPV: Favorable Recommendation for Wound Healing and Inflammatory Conditions

KPV is a three-amino-acid peptide studied in inflammatory signaling, intestinal injury, antimicrobial activity, and specialized delivery systems. The nominated uses were wound healing and inflammatory conditions, including psoriasis and eczema, with proposed topical cream and gel formulations.

FDA reported that it had not identified clinical studies or human-exposure data for KPV through any route and questioned whether preclinical findings could establish effectiveness for the proposed products. PCAC still issued a favorable recommendation, but the vote did not establish clinical efficacy.

TB-500: Favorable Recommendation, but Identity Still Matters

The TB-500 review involved wound healing and a major identity problem. Thymosin beta-4 is a naturally occurring 43-amino-acid peptide, while FDA's materials focused on a much shorter fragment associated with the sequence LKKTETQ. Evidence for the full-length peptide cannot automatically be assigned to that fragment.

PCAC issued a favorable recommendation, but the vote did not prove that the fragment heals human wounds. The identity problem makes sequence, molecular weight, and documentation especially important when reviewing a TB-500 research product.

MOTS-c: Favorable Recommendation for Obesity and Osteoporosis

MOTS-c is a mitochondrial-derived peptide studied in metabolic, exercise, aging, and bone models. Experiments in cells and animals have reported effects involving insulin sensitivity, AMPK signaling, physical capacity, weight gain, and bone loss.

Studies measuring naturally occurring MOTS-c are not trials of administered synthetic MOTS-c. FDA reported no identified human-exposure data for drug products containing the peptide. The modified analog CB4211 has entered human research, but its evidence cannot automatically be transferred to MOTS-c free base or acetate. PCAC's favorable recommendation did not establish a human treatment for obesity or osteoporosis.

Emideltide/DSIP: The Only Peptide Without a Favorable Recommendation

Emideltide, commonly known as DSIP, was evaluated for opioid withdrawal, chronic insomnia, and narcolepsy.

DSIP has appeared in small human studies dating back decades, but the literature used different preparations, routes, endpoints, and designs. Much of it was small, uncontrolled, or difficult to connect to the exact substances under review.

PCAC did not support inclusion. The negative recommendation remains advisory, but it means the committee did not find the case sufficient for a favorable 503A recommendation. Product identity and research-only documentation appear on the DSIP research peptide page.

Epitalon: Favorable Recommendation for Insomnia, Not Longevity

Epitalon is widely discussed in connection with telomeres, melatonin, aging, and longevity. PCAC reviewed only insomnia. Relevant evidence involved pineal function, melatonin rhythms, and the related biological extract Epithalamin—not a modern clinical program proving that synthetic AEDG treats chronic insomnia.

PCAC issued a favorable recommendation despite FDA staff's concerns. It did not validate longevity claims or create an approved sleep treatment. Researchers should distinguish Epitalon from Epithalamin and review the exact identity listed on the Epithalon research peptide page.

Semax: Favorable Recommendation Across Three Neurological Uses

Semax was evaluated for cerebral ischemia, migraine, and trigeminal neuralgia. It has a human research history outside the United States, particularly in ischemic-stroke publications, but much of the literature is older, regionally concentrated, or limited in design.

A stroke study is not a migraine trial, and a migraine report is not proof of benefit in trigeminal neuralgia. PCAC issued a favorable recommendation, but Semax remains unapproved by FDA for these conditions. The Semax research peptide page provides product identity and research-use information.

Why Free Base, Acetate, and Product Identity Matter

FDA's voting questions treated free-base and acetate forms separately because chemical form can affect solubility, stability, formulation, and analytical characterization. A paper using only a common peptide name may not identify the precise salt form, impurity profile, route, or manufacturing controls.

TB-500 adds the distinction between full-length thymosin beta-4 and a shorter fragment; Epitalon research may be conflated with the multi-component extract Epithalamin. For both regulation and laboratory research, sequence, molecular form, analytical identity, stability, and batch documentation matter more than a familiar name.

What Happens After the PCAC Recommendations?

FDA can now consider the recommendations alongside its scientific reviews, meeting record, public comments, quality and safety information, effectiveness evidence, and historical compounding use. FDA states that it addresses evaluated substances through notice-and-comment rulemaking. A proposed rule, final rule, updated list, revised policy, or another formal FDA notice—not the advisory vote alone—would mark a practical change.

Until FDA acts, the accurate status is:

PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion; it did not give Emideltide/DSIP a favorable recommendation. The recommendations are non-binding, none of the seven became FDA-approved, and the votes did not automatically add any substance to the 503A Bulks List.

The Peptide Review Is Continuing

FDA has identified another group for PCAC consideration: cathelicidin LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and pegylated mechano growth factor (PEG-MGF). The next round will revisit many of the same questions about human evidence, route-specific safety, impurities, and product identity.

The Bottom Line

The July meeting moved the 503A discussion forward: six peptide groups received favorable recommendations, while Emideltide/DSIP did not. But it did not settle the scientific evidence or immediately change the federal list. The central distinction is simple:

PCAC made recommendations. FDA has not yet made the final regulatory decisions.

FDA's reviews clarify where evidence is relatively developed, where it remains mostly preclinical, and where identity or formulation problems weaken broad claims. The next meaningful update will come from formal FDA action—not marketing built around the committee vote.